BACKGROUND: Pelvic lymph node metastasis (PLNM) is an important prognostic factor for patients with cervical carcinoma. The objective of this study was to identify a gene-expression signature that could predict PLNM in cervical carcinoma. METHODS: Eighty-eight women with cervical carcinoma with PLNM (n = 23) and without PLNM (n = 65) were divided randomly into a training group and a test group. An oligonucleotide microarray that contained probes for 1440 human cancer-related genes was fabricated in-house and was used to detect the gene expression profile of cervical carcinoma. The gene expression levels detected in the microarray were verified by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). RESULTS: A gene-expression signature for predicting PLNM was developed in patients from the training group, including 11 genes: ribosomal protein L35 (RPL35); thymosin β 10 (TMSB10); tyrosine 3-mono-oxytenase/tryptophan 5-mono-oxygenase activation protein, ζ polypeptide (YWHAZ); biotinidase (BTD); lactate dehydrogenase A (LDHA); glucuronidase β (GUSB); superoxide dismutase 2 (SOD2); nuclear receptor subfamily 3, group C, member 2 (NR3C2); fructosamine 3 kinase (FN3K); x-ray repair cross-complementing 4 (XRCC4); and wingless-type mouse mammary tumor virus integration site family member 2 (WNT2). In the test group, the signature's accuracy, sensitivity, specificity, positive predictive value, and negative predictive value were 91%, 90.9%, 93.9%, 83.3%, and 96.9%, respectively, for predicting PLNM. The expression levels of 5 genes in the signature were confirmed by qRT-PCR. A multivariate analysis demonstrated that patients with 11-gene high-risk scores were had a 33-fold increased risk for PLNM compared with patients who had low-risk scores. The 5-year overall and disease-free survival rates for patients who had 11-gene high-risk scores were marginally significantly lower than the rates for patients who had 11-gene low-risk scores (P = .087 and P = .174, respectively). CONCLUSIONS: In this study, 11-gene signature for predicting PLNM in cervical carcinoma was identified that may help clinicians in planning therapy for patients with cervical carcinoma.
BACKGROUND: Pelvic lymph node metastasis (PLNM) is an important prognostic factor for patients with cervical carcinoma. The objective of this study was to identify a gene-expression signature that could predict PLNM in cervical carcinoma. METHODS: Eighty-eight women with cervical carcinoma with PLNM (n = 23) and without PLNM (n = 65) were divided randomly into a training group and a test group. An oligonucleotide microarray that contained probes for 1440 human cancer-related genes was fabricated in-house and was used to detect the gene expression profile of cervical carcinoma. The gene expression levels detected in the microarray were verified by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). RESULTS: A gene-expression signature for predicting PLNM was developed in patients from the training group, including 11 genes: ribosomal protein L35 (RPL35); thymosin β 10 (TMSB10); tyrosine 3-mono-oxytenase/tryptophan 5-mono-oxygenase activation protein, ζ polypeptide (YWHAZ); biotinidase (BTD); lactate dehydrogenase A (LDHA); glucuronidase β (GUSB); superoxide dismutase 2 (SOD2); nuclear receptor subfamily 3, group C, member 2 (NR3C2); fructosamine 3 kinase (FN3K); x-ray repair cross-complementing 4 (XRCC4); and wingless-type mouse mammary tumor virus integration site family member 2 (WNT2). In the test group, the signature's accuracy, sensitivity, specificity, positive predictive value, and negative predictive value were 91%, 90.9%, 93.9%, 83.3%, and 96.9%, respectively, for predicting PLNM. The expression levels of 5 genes in the signature were confirmed by qRT-PCR. A multivariate analysis demonstrated that patients with 11-gene high-risk scores were had a 33-fold increased risk for PLNM compared with patients who had low-risk scores. The 5-year overall and disease-free survival rates for patients who had 11-gene high-risk scores were marginally significantly lower than the rates for patients who had 11-gene low-risk scores (P = .087 and P = .174, respectively). CONCLUSIONS: In this study, 11-gene signature for predicting PLNM in cervical carcinoma was identified that may help clinicians in planning therapy for patients with cervical carcinoma.
Authors: Pavel Bouchal; Monika Dvořáková; Theodoros Roumeliotis; Zbyněk Bortlíček; Ivana Ihnatová; Iva Procházková; Jenny T C Ho; Josef Maryáš; Hana Imrichová; Eva Budinská; Rostislav Vyzula; Spiros D Garbis; Bořivoj Vojtěšek; Rudolf Nenutil Journal: Mol Cell Proteomics Date: 2015-04-22 Impact factor: 5.911
Authors: Olena Masui; Nicole M A White; Leroi V DeSouza; Olga Krakovska; Ajay Matta; Shereen Metias; Bishoy Khalil; Alexander D Romaschin; R John Honey; Robert Stewart; Kenneth Pace; Georg A Bjarnason; K W Michael Siu; George M Yousef Journal: Mol Cell Proteomics Date: 2012-10-17 Impact factor: 5.911
Authors: Jennifer B Permuth; Ailith Pirie; Y Ann Chen; Hui-Yi Lin; Brett M Reid; Zhihua Chen; Alvaro Monteiro; Joe Dennis; Gustavo Mendoza-Fandino; Hoda Anton-Culver; Elisa V Bandera; Maria Bisogna; Louise Brinton; Angela Brooks-Wilson; Michael E Carney; Georgia Chenevix-Trench; Linda S Cook; Daniel W Cramer; Julie M Cunningham; Cezary Cybulski; Aimee A D'Aloisio; Jennifer Anne Doherty; Madalene Earp; Robert P Edwards; Brooke L Fridley; Simon A Gayther; Aleksandra Gentry-Maharaj; Marc T Goodman; Jacek Gronwald; Estrid Hogdall; Edwin S Iversen; Anna Jakubowska; Allan Jensen; Beth Y Karlan; Linda E Kelemen; Suzanne K Kjaer; Peter Kraft; Nhu D Le; Douglas A Levine; Jolanta Lissowska; Jan Lubinski; Keitaro Matsuo; Usha Menon; Rosemary Modugno; Kirsten B Moysich; Toru Nakanishi; Roberta B Ness; Sara Olson; Irene Orlow; Celeste L Pearce; Tanja Pejovic; Elizabeth M Poole; Susan J Ramus; Mary Anne Rossing; Dale P Sandler; Xiao-Ou Shu; Honglin Song; Jack A Taylor; Soo-Hwang Teo; Kathryn L Terry; Pamela J Thompson; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen; Lynne R Wilkens; Stacey Winham; Yin-Ling Woo; Anna H Wu; Hannah Yang; Wei Zheng; Argyrios Ziogas; Catherine M Phelan; Joellen M Schildkraut; Andrew Berchuck; Ellen L Goode; Paul D P Pharoah; Thomas A Sellers Journal: Hum Mol Genet Date: 2016-07-04 Impact factor: 6.150
Authors: Maria Cecília Ramiro Talarico; Rafaella Almeida Lima Nunes; Gabriela Ávila Fernandes Silva; Larissa Bastos Eloy da Costa; Marcella Regina Cardoso; Sérgio Carlos Barros Esteves; Luis Otávio Zanatta Sarian; Luiz Carlos Zeferino; Lara Termini Journal: Antioxidants (Basel) Date: 2021-05-05
Authors: Anthony K-C So; Jatinder Kaur; Ipshita Kak; Jasmeet Assi; Christina MacMillan; Ranju Ralhan; Paul G Walfish Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240